Abstract
The strategy for innovation at EMA is defined in the Pharmaceutical Legislation (Reg (EC) No 726/2004). EMA has also outlined a Road Map up to 2010 with two main objectives: to stimulate research and innovation from pharmaceutical and biotechnology enterprises within Europe, and to address hurdles encountered during innovative drug development [1]. In order to support the activities on innovative products, the pharmaceutical legislation offers the definitions and references for innovative medicines.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
